| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
679.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$12.17 - $24.61 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
57,878 |
165,115 |
165,115 |
195,533 |
| Total Sell Value |
$1,217,382 |
$3,085,988 |
$3,085,988 |
$4,069,195 |
| Total People Sold |
2 |
2 |
2 |
3 |
| Total Sell Transactions |
4 |
7 |
7 |
14 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Danos Olivier |
Chief Scientific Officer |
• – – |
2019-04-15 |
4 |
OE |
$20.35 |
$40,700 |
D/D |
2,000 |
8,500 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2019-03-21 |
4 |
AS |
$60.64 |
$607,539 |
D/D |
(10,000) |
229,215 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2019-03-19 |
4 |
AS |
$58.21 |
$877,989 |
D/D |
(15,000) |
246,000 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2019-03-19 |
4 |
OE |
$0.85 |
$12,750 |
D/D |
15,000 |
261,000 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2019-03-12 |
4 |
OE |
$20.35 |
$101,750 |
D/D |
5,000 |
6,500 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2019-03-05 |
4 |
AS |
$60.01 |
$184,111 |
D/D |
(3,068) |
239,215 |
|
- |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2019-02-25 |
4 |
AS |
$54.05 |
$286,465 |
D/D |
(5,300) |
39,500 |
|
- |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2019-02-25 |
4 |
OE |
$35.80 |
$189,740 |
D/D |
5,300 |
44,800 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2019-02-15 |
4 |
AS |
$45.96 |
$709,284 |
D/D |
(15,000) |
246,000 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2019-02-14 |
4 |
OE |
$0.85 |
$12,750 |
D/D |
15,000 |
261,000 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2019-02-07 |
4 |
OE |
$0.85 |
$102,000 |
D/D |
120,000 |
242,283 |
|
- |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2019-02-05 |
4 |
AS |
$50.08 |
$2,195,107 |
D/D |
(43,832) |
39,500 |
|
- |
|
| Simpson Curran |
SVP, Product Development & CTO |
• – – |
2019-02-05 |
4 |
OE |
$13.09 |
$1,070,658 |
D/D |
43,832 |
83,332 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2019-02-01 |
4 |
OE |
$0.85 |
$38,250 |
D/D |
45,000 |
246,000 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2019-01-15 |
4 |
AS |
$43.70 |
$657,698 |
D/D |
(15,000) |
201,000 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-12-31 |
4 |
A |
$35.66 |
$12,017 |
D/D |
337 |
3,006 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-12-18 |
4 |
AS |
$46.79 |
$237,698 |
D/D |
(5,000) |
2,669 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-12-18 |
4 |
OE |
$12.10 |
$60,500 |
D/D |
5,000 |
7,669 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2018-12-17 |
4 |
AS |
$46.11 |
$700,927 |
D/D |
(15,000) |
216,000 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2018-12-17 |
4 |
AS |
$45.73 |
$347,650 |
D/D |
(7,500) |
122,283 |
|
- |
|
| Yoo Stephen |
Chief Medical Officer |
• – – |
2018-12-03 |
4 |
AS |
$59.62 |
$1,227,412 |
D/D |
(20,414) |
0 |
|
- |
|
| Yoo Stephen |
Chief Medical Officer |
• – – |
2018-12-03 |
4 |
OE |
$0.85 |
$17,352 |
D/D |
20,414 |
20,414 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2018-12-03 |
4 |
AS |
$60.34 |
$1,208,087 |
D/D |
(20,000) |
231,000 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2018-11-30 |
4 |
OE |
$20.35 |
$30,525 |
D/D |
1,500 |
1,500 |
|
- |
|
| Beshar Luke M |
|
– • – |
2018-11-29 |
4 |
AS |
$65.00 |
$830,960 |
D/D |
(12,784) |
0 |
|
- |
|
404 Records found
|
|
Page 9 of 17 |
|
|
0.24 (1.53%) 
